

Lao PDR Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Lao PDR					
2. Grant number: 1820-LAO-12d-X / 13-LAO-08a-Y/18-LAO-25a-Y					
3. Date of Decision Letter: 13 June 2018					
4. - Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine					
6. Vaccine type: Pneumococcal					
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID					
8. Programme duration¹: 2013 -2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)					
	2013-2017	2018	2019	2020	Total²
Programme Budget (US\$)	7,443,207 ³	1,017,000	1,175,500	954,500	10,590,207
<i>*The 2013-2017 amount reflects the actuals, and is therefore slightly reduced from the December 2017 PCV Decision Letter. The total amount is therefore also amended.</i>					
10. Vaccine introduction grant (in US\$): a VIG of US\$150,000 was disbursed on 8 th July 2013 Product switch grant (in \$US): 45,000					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2013-2017	2018			
Number of Pneumococcal vaccines doses		294,800			
Annual Amounts (US\$)	7,443,207 ⁵	1,017,000			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1820-LAO-12d-X-C

According to the co-financing policy, the Country falls within the Accelerated Transition group as of 1 January 2017.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	118,200	262,200	366,600
Number of AD syringes	112,500		
Number of re-constitution syringes			
Number of safety boxes	1,250		
Value of vaccine doses (US\$)	360,306		
Total co-financing payments (US\$) (including freight)	368,000	816,500	1,141,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes